Swiss National Bank Raises Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Swiss National Bank increased its stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) by 13.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,900 shares of the company’s stock after purchasing an additional 11,000 shares during the quarter. Swiss National Bank owned approximately 0.09% of Tango Therapeutics worth $293,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its stake in shares of Tango Therapeutics by 26.8% during the third quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after buying an additional 489,949 shares during the period. Geode Capital Management LLC raised its holdings in Tango Therapeutics by 11.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock valued at $10,538,000 after acquiring an additional 142,710 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of Tango Therapeutics during the 3rd quarter worth $1,098,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Tango Therapeutics by 18.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 487,237 shares of the company’s stock worth $3,752,000 after purchasing an additional 76,540 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Tango Therapeutics in the fourth quarter valued at $218,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Insider Buying and Selling

In related news, CEO Barbara Weber sold 9,778 shares of Tango Therapeutics stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the transaction, the chief executive officer now owns 1,631,264 shares in the company, valued at approximately $4,877,479.36. The trade was a 0.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 24,268 shares of company stock valued at $72,561. 6.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Tango Therapeutics in a research report on Thursday, December 5th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tango Therapeutics currently has a consensus rating of “Buy” and an average price target of $12.33.

Tango Therapeutics Stock Down 8.7 %

Shares of NASDAQ TNGX opened at $1.47 on Monday. The stock has a market capitalization of $158.92 million, a PE ratio of -1.25 and a beta of 0.87. The firm has a fifty day moving average of $2.37 and a 200-day moving average of $4.02. Tango Therapeutics, Inc. has a 52-week low of $1.43 and a 52-week high of $12.02.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The firm had revenue of $4.12 million for the quarter, compared to analysts’ expectations of $7.84 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. Equities research analysts expect that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.